Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYou can take omeprazole with Mounjaro (tirzepatide). There is no direct pharmacokinetic interaction between them, and omeprazole is commonly used alongside GLP-1 and dual-agonist weight-loss medicines to manage stomach-related side effects. That said, your prescriber should know about every medicine you take before Mounjaro is approved for you, because tirzepatide slows gastric emptying in ways that can affect how other oral medicines are absorbed — and that picture is always assessed individually. Mounjaro is a prescription-only medicine; a clinician reviews your full medication history before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The concern most people bring to this question is reasonable. Tirzepatide slows the rate at which your stomach empties its contents into the small intestine, that is part of how it reduces appetite and blood sugar. If a medicine slows gastric emptying, the thinking goes, surely it must interfere with other tablets you swallow. The reality is more specific than that.
For omeprazole, the evidence does not point to a clinically meaningful problem. Omeprazole is absorbed in the small intestine, and while a slower gastric transit rate can delay when it gets there, peak absorption and overall bioavailability remain broadly stable. The NHS tirzepatide medicines page describes this gastric-emptying effect in context, but does not list omeprazole as a medicine that requires special management alongside tirzepatide. So the myth that the two medicines neutralise each other, or that taking omeprazole will blunt Mounjaro's effectiveness, does not hold up. They operate on completely separate systems: tirzepatide acts on GIP and GLP-1 receptors; omeprazole blocks a proton pump in the stomach wall to reduce acid output.
What remains true is that any change to gastric motility is worth understanding, especially if you take medicines with narrow therapeutic windows, but omeprazole is not in that category for most people. The right step is a straightforward conversation with your prescriber, not quietly stopping either medicine.
There is a practical reason these two medicines keep appearing together. Nausea, indigestion, reflux and stomach discomfort are among the most frequently reported side effects during the early weeks of tirzepatide treatment, particularly around the time of a dose increase. The NHS guidance on tirzepatide lists gastrointestinal symptoms as the most common side effects, and for many people they are at their worst in the first fortnight after starting or titrating up.
Omeprazole (a proton-pump inhibitor available both on prescription and over the counter) directly reduces stomach-acid production, which can take the edge off reflux and that persistent gnawing discomfort some people notice on tirzepatide. It does not treat nausea from a central perspective the way some antiemetics do, but for acid-driven symptoms it is often the most practical first tool. Prescribers and GPs sometimes recommend it proactively when a patient's history suggests they are prone to reflux, rather than waiting for symptoms to appear. If you already take omeprazole regularly and are starting Mounjaro, that is a straightforward piece of information to include in your consultation, not a barrier to treatment. You can read more about how tirzepatide works and what the treatment schedule looks like if you want a fuller picture before your assessment.
Related proton-pump inhibitors come up in similar questions: esomeprazole and Mounjaro and lansoprazole and Mounjaro are covered in their own pages with the same reassurance and the same caveat, tell your prescriber, and let the clinical picture be assessed properly.
Flagging omeprazole to your prescriber is good practice. Flagging certain other medicines is genuinely important. Tirzepatide's slowing of gastric emptying has the potential to affect the absorption of oral medicines that depend on rapid or time-sensitive absorption, medicines with narrow therapeutic windows, for example, or those where peak plasma concentration matters for the effect. Oral contraceptives are one well-documented area: because pill absorption can be reduced during the first weeks of tirzepatide treatment and after each dose increase, NHS guidance recommends adding a non-oral contraceptive method (such as condoms) for four weeks at those points.
For medicines like metronidazole taken alongside Mounjaro, the context is again different. Each medicine has its own absorption profile and clinical significance. The pattern here is the same: no blanket rule applies to all oral tablets equally, which is why a prescriber reviews your complete medication list rather than relying on a single-answer interaction checker. If you are curious about cost and whether a private prescription fits your situation, our overview of Mounjaro pricing in the UK explains what a legitimate prescription service includes.
For anyone taking supplements or OTC products alongside Mounjaro, the same principle applies: mention everything at consultation, and let the prescriber make the call.
List it. That is genuinely the whole action. When you fill in your consultation (at nume or with any regulated prescriber) include omeprazole in your current medicines, whether it is prescribed by your GP or bought over the counter. The prescriber at our GPhC-registered pharmacy reviews your answers personally, not through an automated filter, and will note omeprazole in the context of your full health picture. If anything requires follow-up, you will hear from them the same day.
There is no reason to stop omeprazole before starting, and no reason to assume the two cannot coexist. If you develop new or worsening stomach symptoms after beginning tirzepatide (particularly severe pain that spreads to your back) that is a different matter entirely. The MHRA highlighted acute pancreatitis as a known, infrequent but potentially serious side effect of GLP-1 medicines; you can report suspected side effects directly at the MHRA's Yellow Card scheme. Ordinary reflux or indigestion is common and manageable; severe, persistent pain is a reason to seek urgent medical help and should not be attributed to routine side effects without a clinical assessment.
Once your prescription is approved, your treatment arrives via DPD the next working day in plain, unbranded packaging, the pen itself is discreet and no larger than a thick marker. Starting your free consultation takes a few minutes and puts you in front of a real prescriber the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.